Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Oragenics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
OGEN
American
8731
https://www.oragenics.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Oragenics Inc
Oragenics, Inc. Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards
- Apr 19th, 2024 9:50 pm
Oragenics, Inc. Files 10K and Provides Company Update
- Apr 1st, 2024 1:05 pm
Oragenics Appoints James Kelly MD, Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion
- Mar 18th, 2024 11:00 am
15 Highest Quality Probiotics For Gut Health
- Mar 17th, 2024 12:38 pm
Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat Concussion
- Mar 5th, 2024 12:45 pm
Oragenics Announces Closing of Public Offering
- Mar 1st, 2024 9:04 pm
Oragenics Announces Pricing of Public Offering
- Feb 28th, 2024 2:25 am
Oragenics Announces Proposed Public Offering
- Feb 27th, 2024 9:33 pm
Oragenics, Inc. Announces Leadership Transition
- Feb 12th, 2024 9:41 pm
Oragenics, Inc. Announces Expiration of Its Investment Banking Engagement Agreement
- Feb 7th, 2024 1:00 pm
Oragenics, Inc. Preparing for Phase II Clinical Trials to Treat Concussion
- Feb 5th, 2024 1:00 pm
Oragenics Announces Termination of At-The-Market Offering Program
- Jan 23rd, 2024 10:34 pm
Oragenics Completes Acquisition of Odyssey Health’s Neurological Assets
- Jan 2nd, 2024 12:30 pm
Oragenics Issues Update to Shareholders
- Nov 2nd, 2023 11:00 am
Oragenics Announces Appointment of Bruce Cassidy and John Gandolfo to Board of Directors
- Oct 18th, 2023 12:30 pm
Oragenics to Acquire Odyssey Health’s Neurological Drug Technology Pipeline Including Concussion Drug Candidate
- Oct 5th, 2023 10:30 am
Oragenics Enters into Agreement with Lantern Bioworks for Replacement-Therapy Assets
- Sep 29th, 2023 8:00 pm
Oragenics, Inc. Announces Private Placement
- Aug 7th, 2023 12:30 pm
Oragenics Project to Develop a Variant-Agnostic Protein Antigen for Use in its COVID-19 Intranasal Vaccine Receives Funding from CQDM
- Jun 5th, 2023 8:18 pm
Scroll